BAM Logo

CRC - Colorectal Carcinoma

[CRC - Kolorektální karcinom]

EPTIS factsheet 645488 | Last revision 2020-03-26 | URL: https://www.eptis.bam.de/pts645488 https://www.eptis.bam.de/pts645488

PT provider
PT provider SEKK SEKK
Based in Czech Republic
Language(s) English, Czech
Remarks Complete EQA Plan is available here: http://www.sekk.cz/eqa/EQA_1.htm
Product groups Health care / medical devices
Human test material
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Every participant receives 3 sections of each primary sample (6 µm thick). One section is to be used for hematoxylin-eosin (HE) staining and the remaining 2 sections for DNA isolation and mutation detection. -
1 set containing 30 unstained FFPE sections obtained from 10 primary samples (invasive colorectal adenocarcinomas). Detection of KRAS, NRAS, BRAF genes mutations clinically relevant to anti-EGFR therapy Participant's routine method
Aims of the PT scheme
Target group of participants medical laboratories
Linked to specific legislation / standards ISO 17043
Additional, subsidiary aims
Number of participants 50
Accredited or otherwise reviewed by a 3rd party

Approved by European Society of Pathology (ESP)

Operation is commissioned / requested by
Fees and frequency
Participation fee Participation in the scheme: 490 EUR. This price is final and includes both VAT and the samples, transport and evaluation costs.
Regularly operated Yes (1 round per year)
Year of first operation 2019
Contact details of the PT provider
Provider Contact person
53001 Pardubice
Czech Republic

Phone: +420 466530230
Web: http://www.sekk.cz http://www.sekk.cz
Ing. Marek Budina
Phone: +420 466530230
Email: sekk@sekk.cz sekk@sekk.cz
If you find any mistakes please contact the responsible EPTIS coordinator in Czech Republic, Ms Simona Klenovská. Ms Simona Klenovská.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.21